Pruitthealth-rockingham Medicare and Medicaid Location: 804 South Long Drive, Rockingham, North Carolina 28379 Ratings: Phone: (910) 997-4493 |
News Archive
While the development of therapies designed to block "checkpoints" within the immune system has been one of the most exciting and noteworthy advances in cancer research in recent years, it's also been one of the most puzzling, leaving researchers to ask: Why don't these new therapies work for more patients, and why is their efficacy in controlling cancerous tumors often short-lived? A research team from Roswell Park Cancer Institute has shown that at least one answer -; and an excellent opportunity for unleashing the full potential of these promising immunotherapies -; may lie in the body's "fight or flight" reaction to stressors and in drugs already widely used to control and temporarily disable this stress response.
On January 24, 2013, Iris Vega-Figueroa's life changed completely. That's the day she gave birth to her twin girls, Iris and Geraldine. The twins were monoamniotic-monochorionic, meaning they shared one amniotic sack and one placenta in the womb. These rare pregnancies are considered high risk because of the uneven blood flow that occurs between the infants through the placenta.
Greater Than AIDS and GYT: Get Yourself Tested, two leading national campaigns committed to reducing the spread of HIV and other sexually transmitted diseases, are teaming up for a second year to encourage Americans to get tested and know their status.
Covidien plc today announced the results from its Annual General Meeting. Five proposals were on the meeting agenda
Zacharon Pharmaceuticals, Inc. today announced that the company has entered into a strategic research collaboration with Pfizer Inc. to develop drugs for orphan diseases, including lysosomal storage disorders. The potential value of the collaboration to Zacharon is approximately USD $210 million. The collaboration includes the potential development of compounds that may be discovered using Zacharon's innovative platform for developing small molecule drugs targeting specific carbohydrate polymers or glycans.
› Verified 1 days ago